420 related articles for article (PubMed ID: 30025443)
1. Comparison of Efficacy of Pembrolizumab between Epstein-Barr Virus‒Positive and ‒Negative Relapsed or Refractory Non-Hodgkin Lymphomas.
Kim SJ; Hyeon J; Cho I; Ko YH; Kim WS
Cancer Res Treat; 2019 Apr; 51(2):611-622. PubMed ID: 30025443
[TBL] [Abstract][Full Text] [Related]
2. Determination of frequency of epstein-barr virus in non- Hodgkin lymphomas Using EBV latent membrane protein 1 (EBV-LMP1) immunohistochemical staining.
Ishtiaq S; Hassan U; Mushtaq S; Akhtar N
Asian Pac J Cancer Prev; 2013; 14(6):3963-7. PubMed ID: 23886215
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus recruits PDL1-positive cells at the microenvironment in pediatric Hodgkin lymphoma.
Jimenez O; Colli S; Garcia Lombardi M; Preciado MV; De Matteo E; Chabay P
Cancer Immunol Immunother; 2021 Jun; 70(6):1519-1526. PubMed ID: 33184699
[TBL] [Abstract][Full Text] [Related]
4. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase.
Kwong YL; Chan TSY; Tan D; Kim SJ; Poon LM; Mow B; Khong PL; Loong F; Au-Yeung R; Iqbal J; Phipps C; Tse E
Blood; 2017 Apr; 129(17):2437-2442. PubMed ID: 28188133
[TBL] [Abstract][Full Text] [Related]
5. Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma.
Li X; Cheng Y; Zhang M; Yan J; Li L; Fu X; Zhang X; Chang Y; Sun Z; Yu H; Zhang L; Wang X; Wu J; Li Z; Nan F; Tian L; Li W; Young KH
J Hematol Oncol; 2018 Jan; 11(1):15. PubMed ID: 29386072
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of PD1/PDL1 Expression and Their Clinicopathologic Association in EBV-associated Lymphoproliferative Disorders in Nonimmunosuppressed Patients.
Guo L; Bodo J; Durkin L; Hsi ED
Appl Immunohistochem Mol Morphol; 2019 Feb; 27(2):101-106. PubMed ID: 29084057
[TBL] [Abstract][Full Text] [Related]
7. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.
Kataoka K; Miyoshi H; Sakata S; Dobashi A; Couronné L; Kogure Y; Sato Y; Nishida K; Gion Y; Shiraishi Y; Tanaka H; Chiba K; Watatani Y; Kakiuchi N; Shiozawa Y; Yoshizato T; Yoshida K; Makishima H; Sanada M; Onozawa M; Teshima T; Yoshiki Y; Ishida T; Suzuki K; Shimada K; Tomita A; Kato M; Ota Y; Izutsu K; Demachi-Okamura A; Akatsuka Y; Miyano S; Yoshino T; Gaulard P; Hermine O; Takeuchi K; Ohshima K; Ogawa S
Leukemia; 2019 Jul; 33(7):1687-1699. PubMed ID: 30683910
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial.
Geoerger B; Kang HJ; Yalon-Oren M; Marshall LV; Vezina C; Pappo A; Laetsch TW; Petrilli AS; Ebinger M; Toporski J; Glade-Bender J; Nicholls W; Fox E; DuBois SG; Macy ME; Cohn SL; Pathiraja K; Diede SJ; Ebbinghaus S; Pinto N
Lancet Oncol; 2020 Jan; 21(1):121-133. PubMed ID: 31812554
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus detection in non-Hodgkin's lymphoma of the oral cavity: an immunocytochemical and in situ hybridization study.
Leong IT; Fernandes BJ; Mock D
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Aug; 92(2):184-93. PubMed ID: 11505266
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death-ligand 1 (PD-L1) axis in post-transplant lymphoproliferative disorders: association with Epstein-Barr virus, PD-L1 copy number alterations, and outcome.
Veloza L; Teixido C; Castrejon N; Climent F; Carrió A; Marginet M; Soldini D; González-Farré B; Ribera-Cortada I; Lopez-Guillermo A; González-Barca E; Sierra A; Herrera M; Gómez C; Garcia A; Balagué O; Campo E; Martinez A
Histopathology; 2019 Dec; 75(6):799-812. PubMed ID: 30861172
[TBL] [Abstract][Full Text] [Related]
11. Primary non-Hodgkin's lymphoma of the intestine: high prevalence of Epstein-Barr virus in Mexican lymphomas as compared with European cases.
Quintanilla-Martínez L; Lome-Maldonado C; Ott G; Gschwendtner A; Gredler E; Reyes E; Angeles-Angeles A; Fend F
Blood; 1997 Jan; 89(2):644-51. PubMed ID: 9002968
[TBL] [Abstract][Full Text] [Related]
12. Comparison of genomic alterations in Epstein-Barr virus-positive and Epstein-Barr virus-negative diffuse large B-cell lymphoma.
Liu F; Tian S; Liu Q; Deng Y; He Q; Shi Q; Chen G; Xu X; Yuan J; Nakamura S; Karube K; Wang Z
Cancer Med; 2024 Feb; 13(4):e6995. PubMed ID: 38457199
[TBL] [Abstract][Full Text] [Related]
13. Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin's lymphoma.
Lurain K; Ramaswami R; Mangusan R; Widell A; Ekwede I; George J; Ambinder R; Cheever M; Gulley JL; Goncalves PH; Wang HW; Uldrick TS; Yarchoan R
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33608378
[TBL] [Abstract][Full Text] [Related]
14. Expression of co-inhibitory molecules B7-H4 and B7-H1 in Epstein-Barr virus positive diffuse large B-cell lymphoma and their roles in tumor invasion.
Jiang Y; Lin J; Zhang J; Lu S; Wang C; Tong Y
Pathol Res Pract; 2019 Dec; 215(12):152684. PubMed ID: 31679792
[TBL] [Abstract][Full Text] [Related]
15. Enhanced PD-L1 Expression in LMP1-positive Cells of Epstein-Barr Virus-associated Malignant Lymphomas and Lymphoproliferative Disorders: A Single-cell Resolution Analysis With Multiplex Fluorescence Immunohistochemistry and In Situ Hybridization.
Kume A; Shinozaki-Ushiku A; Kunita A; Kondo A; Ushiku T
Am J Surg Pathol; 2022 Oct; 46(10):1386-1396. PubMed ID: 35605962
[TBL] [Abstract][Full Text] [Related]
16. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
[TBL] [Abstract][Full Text] [Related]
17. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
18. Primary nasopharyngeal non-Hodgkin lymphoma and its relationship with Epstein-Barr virus infection.
Zhang B; Zong Y; He J; Zhong B; Lin S
Chin Med J (Engl); 2003 Jun; 116(6):913-7. PubMed ID: 12877806
[TBL] [Abstract][Full Text] [Related]
19. Frequent traces of EBV infection in Hodgkin and non-Hodgkin lymphomas classified as EBV-negative by routine methods: expanding the landscape of EBV-related lymphomas.
Mundo L; Del Porro L; Granai M; Siciliano MC; Mancini V; Santi R; Marcar L; Vrzalikova K; Vergoni F; Di Stefano G; Schiavoni G; Segreto G; Onyango N; Nyagol JA; Amato T; Bellan C; Anagnostopoulos I; Falini B; Leoncini L; Tiacci E; Lazzi S
Mod Pathol; 2020 Dec; 33(12):2407-2421. PubMed ID: 32483241
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological features and EBV infection status of lymphoma in children and adolescents in South China: a retrospective study of 662 cases.
Qin C; Huang Y; Feng Y; Li M; Guo N; Rao H
Diagn Pathol; 2018 Feb; 13(1):17. PubMed ID: 29482573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
